Pozanicline for the treatment of attention-deficit/hyperactivity disorder

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  2014-10-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/13543784.2014.956078PMID 25196198
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cholinergic modulation of the medial prefrontal cortex: the role of nicotinic receptors in attention and regulation of neuronal activity

  2014cited by this paper
• AZD3480, a novel nicotinic receptor agonist, for the treatment of attention-deficit/hyperactivity disorder in adults.

  2014cited by this paper
• A randomized, double-blind, placebo-controlled crossover study of α4β2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder

  2014cited by this paper
• Practitioner Review: What have we learnt about the causes of ADHD?

  2013cited by this paper
• Cognition as a therapeutic target in late-life depression: potential for nicotinic therapeutics.

  2013cited by this paper
• Complex relationships of nicotinic receptor actions and cognitive functions.

  2013cited by this paper
• Efficacy and Safety of Lisdexamfetamine Dimesylate and Atomoxetine in the Treatment of Attention-Deficit/Hyperactivity Disorder: a Head-to-Head, Randomized, Double-Blind, Phase IIIb Study

  2013cited by this paper
• Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options

  2012cited by this paper
• Discovery of 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (TC-6683, AZD1446), a novel highly selective α4β2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders.

  2012cited by this paper
• A randomized pilot study of the efficacy and safety of ABT-089, a novel α4β2 neuronal nicotinic receptor agonist, in adults with attention-deficit/hyperactivity disorder.

  2012cited by this paper
• Alpha7 nicotinic cholinergic neuromodulation may reconcile multiple neurotransmitter hypotheses of schizophrenia.

  2012cited by this paper
• Efficacy and safety of the novel α4β2 neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study

  2012cited by this paper
• Assessment of the effects of AZD3480 on cognitive function in patients with schizophrenia.

  2012cited by this paper
• ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents

  2012cited by this paper
• Nicotinic Acetylcholine Receptor β2 Subunits in the Medial Prefrontal Cortex Control Attention

  2011cited by this paper
• Cholinergic modulation of cognition: Insights from human pharmacological functional neuroimaging

  2011cited by this paper
• A randomized double-blind study comparing 25 and 50 mg TC-1734 (AZD3480) with placebo, in older subjects with age-associated memory impairment

  2011cited by this paper
• ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents

  2011cited by this paper
• Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder.

  2011cited by this paper
• Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials.

  2011cited by this paper
• Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis

  2010influential reference
• Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children --- United States, 2003 and 2007.

  2010cited by this paper
• How persistent is ADHD? A controlled 10-year follow-up study of boys with ADHD.

  2010cited by this paper
• Mechanisms of Neuroprotective Effects of Nicotine and Acetylcholinesterase Inhibitors: Role of α4 and α7 Receptors in Neuroprotection

  2009cited by this paper
• Selectivity of ABT-089 for alpha4beta2* and alpha6beta2* nicotinic acetylcholine receptors in brain.

  2009cited by this paper
• Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial.

  2009influential reference
• Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.

  2008cited by this paper
• The potential of neuronal nicotinic acetylcholine receptor agonists for treating CNS conditions

  2008cited by this paper
• Prefrontal acetylcholine release controls cue detection on multiple timescales.

  2007cited by this paper
• Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system.

  2007cited by this paper
• Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder.

  2007cited by this paper
• Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder.

  2007cited by this paper
• ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders.

  2006influential reference
• ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study.

  2006cited by this paper
• Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization

  2006cited by this paper
• Neuronal nicotinic receptors: from structure to pathology.

  2004cited by this paper
• The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry

  2002cited by this paper
• Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder.

  2001cited by this paper
• Sustained Visual Attention Performance-Associated Prefrontal Neuronal Activity: Evidence for Cholinergic Modulation

  2000cited by this paper
• A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder.

  1999cited by this paper
• ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties.

  1997cited by this paper
• Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD).

  1996cited by this paper
• The cerebral cortex of the rat and visual attentional function: dissociable effects of mediofrontal, cingulate, anterior dorsolateral, and parietal cortex lesions on a five-choice serial reaction time task.

  1996cited by this paper
• [Affective disorders in the fourth edition of the classification of mental disorders prepared by the American Psychiatric Association -- diagnostic and statistical manual of mental disorders].

  1993cited by this paper

• Serotonergic and Adrenergic Neuroreceptor Manipulation Ameliorates Core Symptoms of ADHD through Modulating Dopaminergic Receptors in Spontaneously Hypertensive Rats

  2024cites this paper
• Viloxazine extended-release capsules for the treatment of attention-deficit/ hyperactivity disorder in adult patients

  2023cites this paper
• Potential Targets and Action Mechanism of Gastrodin in the Treatment of Attention-Deficit/Hyperactivity Disorder: Bioinformatics and Network Pharmacology Analysis

  2022cites this paper
• Reviewing the role of emerging therapies in the ADHD armamentarium

  2020cites this paper
• Designing selective modulators for the nicotinic receptor subtypes: challenges and opportunities.

  2018cites this paper
• The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data

  2018cites this paper
• Nicotinic α4β2 Cholinergic Receptor Influences on Dorsolateral Prefrontal Cortical Neuronal Firing during a Working Memory Task

  2017cites this paper
• Prenatal Alcohol Exposure in Rodents As a Promising Model for the Study of ADHD Molecular Basis

  2016cites this paper
• Current Investigational Drugs for the Treatment of Attention-Deficit/Hyperactivity Disorder

  2016cites this paper
• Neuronal effects of nicotine during auditory selective attention

  2014cites this paper